About
An early-stage biotechnology company
ProteoThera, Inc. is an early stage biotechnology company that is advancing drug targeting technology. The Company’s transformative platform technology, a proprietary tissue matrix-binding (MB) protein fusion technology, is being developed to improve clinical efficacy and safety of FDA approved and validated therapeutics to create a new paradigm in the treatment of autoinflammatory diseases and in tissue regeneration.
ProteoThera’s focus on previously validated or approved therapies greatly de-risks clinical, regulatory, and commercial pathways.
The MB technology can generate new pharmacokinetic profiles for therapies, transforming systemically delivered drugs into locally or subcutaneous delivered proteins, peptides, and small molecules. By keeping therapies where they are needed to enable therapeutic effect, the MB platform may also improve the safety profile by reducing or eliminating side effects associated with whole-body systemic exposure. The MB targeting technology was developed at Brigham & Women’s Hospital, Harvard Medical School.
ProteoThera’s first development priority is the use of PRT-1000 (Matrix-Binding Interleukin 1 Receptor Antagonist) for treatment of acute gout pain. IL1RA is a potent cytokine inhibitor, already FDA approved for systemic administration in rheumatoid arthritis.
Where the technology came from
The MB targeting technology was developed at Brigham & Women’s Hospital, Harvard Medical School, and the Harvard University Department of Stem Cell and Regenerative Biology.
Why it exists
New pharmacokinetics from known drugs
Local instead of systemic
Systemically delivered drugs become locally delivered proteins, peptides and small molecules.
De-risked
Starting from FDA-approved or previously validated therapeutics shortens the clinical, regulatory and commercial path.
Safer by design
Keeping a drug where it is needed may reduce the side effects of whole-body exposure.
Support and partners
Built with public and private backing
